Caerulomycin A enhances transforming growth factor-β (TGF-β)-smad3 protein signaling by suppressing interferon-γ (IFN-γ)-signal transducer and activator of transcription 1 (STAT1) protein signaling to expand regulatory T cells (Tregs) by Gurram, Rama Krishna et al.
Caerulomycin A Enhances Transforming Growth Factor-
(TGF-)-Smad3 Protein Signaling by Suppressing Interferon-
 (IFN-)-Signal Transducer and Activator of Transcription 1
(STAT1) Protein Signaling to Expand Regulatory T Cells
(Tregs)*
Received for publication,December 24, 2013, and in revised form, April 21, 2014 Published, JBC Papers in Press,May 8, 2014, DOI 10.1074/jbc.M113.545871
Rama Krishna Gurram1, Weshely Kujur1, Sudeep K. Maurya1, and Javed N. Agrewala2
From the Immunology Laboratory, Institute of Microbial Technology (Council of Scientific and Industrial Research),
Chandigarh 160036, India
Background: Caerulomycin A, a known antifungal agent, was explored for its novel immunomodulatory activity.
Results: Caerulomycin A supports the generation of Tregs by augmenting the TGF--Smad3 and suppressing the IFN--
STAT1 signaling pathways by enhancing SOCS1 expression.
Conclusion: Caerulomycin A induces and enhances the Treg population.
Significance:CaerulomycinA can be a potent future drug for treating autoimmune diseases by eliciting the generation of Tregs.
Cytokines play a very important role in the regulation of
immune homeostasis. Regulatory T cells (Tregs) responsible for
the generation of peripheral tolerance are under the tight regu-
lation of the cytokinemilieu. In this study, we report a novel role
of a bipyridyl compound, Caerulomycin A (CaeA), in inducing
the generation of Tregs. It was observed that CaeA substantially
up-regulated the pool of Tregs, as evidenced by an increased
frequency of CD4 Foxp3 cells. In addition, CaeA significantly
suppressed the number of Th1 andTh17 cells, as supported by a
decreased percentage of CD4/IFN- and CD4/IL-17 cells,
respectively. Furthermore, we established the mechanism and
observed that CaeA interfered with IFN--induced STAT1 sig-
naling by augmenting SOCS1 expression. An increase in the
TGF--mediated Smad3 activity was also noted. Furthermore,
CaeA rescued Tregs from IFN--induced inhibition. These
results were corroborated by blocking Smad3 activity, which
abolished the CaeA-facilitated generation of Tregs. In essence,
our results indicate a novel role of CaeA in inducing the gener-
ation of Tregs. This finding suggests that CaeA has enough
potential to be considered as a potent future drug for the treat-
ment of autoimmunity.
The immune system of the body is its artillery against patho-
gens. The immune response is very precisely tuned and tamed
to discriminate self fromnon-self. Although the body does gen-
erate autoreactive T cells, the immune system has an accurate
mechanism to eliminate such cells during thymic selection (1).
Paradoxically, some autoreactive T cells can still escape dele-
tion, establish themselves in the body, and become a potential
threat to the host by generating autoimmune diseases. The
body has developed additional defense mechanisms against
these treacherous cells through the induction of peripheral tol-
erance, anergy/unresponsiveness, release of immunosuppres-
sive molecules (TGF-, IL-10, IL-35, etc.), and generation of
regulatory T cells (Tregs)3 (2–4). Despite extremely careful
mechanisms operating in the body to safeguard against autore-
active T cells, these cells may still become activated and can be
terrifically devastating in inflicting injury by causing autoim-
mune diseases (5).
Autoimmune diseases can be treated by non-steroidal anti-
inflammatory drugs, corticosteroids, disease-modifying anti-
rheumatic drugs, and immunosuppressive agents (6). However,
the limitations and side effects associated with the use of these
drugs pave the way toward better and safer remedial measures
(7–9). Recently, the generation of antigen-specific tolerance by
Tregs has gained considerable impetus following the observa-
tion that these cells are endowed with enough potential to sup-
press autoimmune reactions (10, 11).
Tregs are a subset of CD4 helper T cells that specifically
express fork head family transcription factor 3 (Foxp3) (12, 13).
Recently, several strategies have been undertaken to enhance
the production of Tregs for treating autoimmune diseases (14,
15). Naïve CD4 T cells can be differentiated into Tregs by
TGF- (16). Furthermore, Tregs can be increased by antago-
nizing TNF- activity (17). Interestingly, it has also been
reported that rapamycin (Rapa), an immunosuppressive drug,
can successfully expand Tregs (18). Additionally, LY294002 is
also known to induce Tregs (19). Unfortunately, Rapa increases
the chance of diabetes (20).
It is a well known fact that most of the revolutionary medi-
cines, like Rapa, cyclosporinA, and FK506, exhibiting antibiotic
* This work was supported by the Council of Scientific and Industrial
Research.
1 Recipient of fellowships of the Council of Scientific and Industrial Research,
New Delhi, India.
2 To whom correspondence should be addressed: Immunology Labora-
tory, Institute of Microbial Technology (Council of Scientific and Indus-
trial Research), Sector 39A, Chandigarh 160036, India. E-mail: javed@
imtech.res.in.
3 The abbreviations used are: Treg, regulatory T cell; Rapa, rapamycin; CaeA,
Caerulomycin A; Ab, antibody; qPCR, quantitative PCR.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 25, pp. 17515–17528, June 20, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
JUNE 20, 2014•VOLUME 289•NUMBER 25 JOURNAL OF BIOLOGICAL CHEMISTRY 17515
 by guest on D
ecem
ber 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
or antifungal properties were later proven to possess potent
immunosuppressive activity (21–23). CaeA is a bipyridyl com-
pound and has been reported in the literature to show antifun-
gal and antibiotic properties (24, 25).Hence, it encouraged us to
study whether CaeA could also exhibit immunosuppression, in
particular by evoking the generation ofTregs, as observed in the
case of Rapa (18).
In this study, we have shown that CaeA independently
induced Tregs (cTregs) and synergistically supported the TGF-
-mediated expansion of Tregs (cTregs).We also revealed the
mechanism of action involved in the generation of Tregs by
CaeA. Finally, the proof of concept was established by success-
fully treating animals suffering from arthritis with CaeA.
EXPERIMENTAL PROCEDURES
Mice—Female C3He and BALB/c mice and male DBA/1
mice 6–8 weeks of age were procured from the experimental
animal facility of the Institute of Microbial Technology. The
study was approved by the Institutional Animal Ethical
Committee.
Chemicals and Antibodies—The chemicals and reagents
were procured from Sigma-Aldrich (St. Louis, MO) or as men-
tioned otherwise. RPMI 1640, FBS, and TRIzol reagent were
procured from Invitrogen. Penicillin, streptomycin, and pyru-
vic acid were from Serva (Heidelberg, Germany). Phosphatase
inhibitor mixture, STAT1, and Smad3 oligo were from Santa
Cruz Biotechnology (Dallas, TX). CaeA was from LKT Labora-
tories (St. Paul, MN). Anti-phospho-STAT1, anti-phospho-
STAT3, anti-phospho-STAT4, and anti-phospho-STAT6 and
total STAT1, STAT3, STAT4, and STAT6 were from BD Bio-
sciences. Anti-phospho-Smad3 and total Smad3, Smad7, and
JAK1 Abs were from Abcam (Cambridge, MA). Anti-JAK2 Ab
andproteinG-agarose beadswere fromCell SignalingTechnol-
ogy (Danvers, MA).
Medium—All the experiments were carried out in RPMI
1640 supplemented with penicillin (70 mg/liter), streptomycin
(100 mg/liter), NaHCO3 (2.2 g/liter), HEPES (2.38 g/liter), pyr-
uvic acid (110 mg/liter), and FBS (10%).
In Vitro Th Cell Differentiation—Naïve CD4 T cells (2 
105/ml) were stimulated using plate-bound anti-CD3 Ab (2
g/ml) and soluble anti-CD28 Ab (1 g/ml) along with follow-
ing polarizing conditions to differentiate them in to different
Th subsets. Tregs were generated by providing the polarizing
conditions using TGF-: 5 ng/ml  IL-2: 100 units/ml for 5
days; Th1 cells by incubating with IL-12: 5 ng/ml  anti-IL-4
Ab: 10 g/ml  IL-2: 100 units/ml for 4 days; Th17 cells by
culturing with IL-6: 40 ng/ml TGF-: 2.5 ng/ml anti-IL-4
Ab: 10 g/ml anti-IFN- Ab: 10 g/ml for 4 days. In case of
Th1 and Th17 cells, media supplemented with their respective
polarizing cytokines were replenished and cells were cultured
for additional 2 days. The purity of Tregs, Th1, and Th17 was
measured by intracellular expression of Foxp3, IFN-, and
IL-17, respectively. Before harvesting from the cultures, Th1
and Th17 cells were treated with phorbol 12-myristate 13-ace-
tate (40 nM) and ionomycin (1 M) for 2 h. To block cytokine
secretion, brefeldin A (10 g/ml) was added. Later, and cells
were incubated further for 3 h. Tregs, Th1, and Th17 cells were
cultured with different concentrations of CaeA (0–0.15 M).
The modulation in the frequency of Tregs, Th1, and Th17 cells
was analyzed by flow cytometry.
Treg Functional Assay—CD4T cell activationwas performed
as described elsewhere (26). Briefly, CD4 T cells (2 105 cells/
200 l) were stimulated with anti-CD3 and CD28 Abs. Tregs
were added to the cultures and incubated for 48 h. Later, cells
were harvested and studied for activation by flow cytometry.
An alloresponse experiment was performed using spleno-
cytes (2 105) ofMHC-mismatched strains ofmice. TheC3He
(H-2k) cells served as the responder and -irradiated DBA/1
(H-2q) cells as the stimulator. Alloresponse cultures were set in
the presence or absence of Tregs for 4 days. Later, cultures were
pulsed with 1 Ci of [methyl-3H] thymidine for 16 h. The cells
were harvested onto glass filter mats, and incorporated radio-
activity was measured as counts per minutes by scintillation
counting.
Generation of the Experimental Arthritis Model and Disease
Assessment—The induction of arthritis and disease symptoms
were monitored as described previously (27). Briefly, male
DBA/1 mice (6 mice/group) were immunized intradermally on
day 0 with bovine collagen type II (100 g) emulsified in com-
plete Freund adjuvant (4 mg/ml desiccated Mtb H37Ra). A
booster dose of bovine collagen type II in incomplete Freund
adjuvant was injected on day 21. Later, CaeA (1 and 10 mg/kg
body weight) and 0.5% carboxyl methyl cellulose emulsion in
water was administered daily for 50 days, and animals were
monitored every day for arthritis symptoms. A group treated
with carboxyl methyl cellulose (0.5%) was taken as a vehicle
control (placebo). Disease progression was assessed for a clin-
ical score using following criteria: 0, no symptoms; 1, mild
erythema and inflammation in the limb digits; 2, severe
inflammation up to the paw; and 3, severe inflammation up
to the ankle region. These score norms were adopted for
each limb.
For immunological assays, animals were sacrificed on day 30.
The optimum response was reported during that period (28).
The cells isolated from the lymph nodes were pooled and in
vitro-challenged with bovine collagen type II (50 g) for 72 h.
Later, proinflammatory cytokines (IFN- and TNF-) in the
culture supernatants weremeasured by ELISA according to the
instructions of the manufacturer. The proinflammatory mark-
ers matrix metalloproteinase-3 in the serum and IL-6, TNF-,
and IFN- in the knee joints were estimated on day 50. For
histopathological analysis, the knee joints were fixed in buff-
ered formalin (10%) and decalcified in formic acid (1%).
Microtome sections of paraffin-embedded knee joints were
stained with H&E to observe the extent of inflammation.
Fluorescence Imaging—The fluorescence imaging of arthri-
tis-induced mice was performed with the help of the in vivo
imager FMT 2500 Lx (PerkinElmer Life Sciences, Waltham,
MA). ProSense 680 and 750 (cathepsin-specific activatable
probes) and OsteoSense 680 and 800 (specific for bone degen-
eration) were used for visualizing inflammatory responses.
These reagents were injected intravenously 24 h prior to imag-
ing. Later on, hairs were removed by hair clipper and depilatory
cream. The animals were imaged under a given laser wave
length for excitation (680, 750, and 780 nm) and emission fluo-
rescence (700, 780, and 805 nm). All procedures were per-
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formed under gas anesthesia (isoflurane). The intensity of fluo-
rescencewas directly proportional to the severity of the disease.
Image processing and analysis was performed by TrueQuant
software.
Isolation of Naïve CD4 TCells—CD4T cells were isolated
by magnetic activated cell sorting according to the instructions
of the manufacturer (CD4 T cell enrichment kit, BD Biosci-
ences). Briefly, splenocytes obtained from two mice were
FIGURE1.CaeAaloneand inconjunctionwithTGF-augments thepoolofTregs.NaïveCD4Tcells stimulatedwith anti-CD3andCD28Abswere incubated
with either Tregs or Th1 or Th17 polarization conditions and different concentrations of CaeA. The cells were analyzed for the expression of Foxp3, IFN-, and
IL-17 tomonitor the frequency of Tregs, Th1, and Th17, respectively. A, the augmented population of Foxp3 CD4 T cells is indicated by the percentage in the
insets of the flow cytometry contour plots. B, Data are mean S.E. C, fold change by RT-qPCR. Rapa is used as a positive control. D, the decline in the yield of
IFN- and IL-17 by CaeA treatment is depicted by the percentage in the insets of the flow cytometry histograms. E, data aremean S.E. F, picograms/milliliters
estimated through ELISA. G, flow cytometry histograms depicting the decrease in CD44 expression. H, the increase in mitochondrial membrane potential on
CaeA treatment. The control cultures comprises cells incubatedwithmediumalone (noCaeAor TGF-) or in the presence of TGF- alone (noCaeA). *, p 0.05;
**, p0.005; ***, p0.0001. The results shown are from three to five independent experiments.
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pooled and RBC-depleted by ACK (ammonium-chloride-po-
tassium) lysis buffer. Later, the cells were incubatedwithCD4T
cell enrichment mixture (50 l/107 cells) and biotin anti-CD25
Ab (5 l/107 cells) for 30 min at 4 °C. The unbound Abs were
removed by washing with RPMI 1640 (400 g, 5 min). The resid-
ual pellet was incubated with BDTM IMag streptavidin particles
plus-DM (50 l/107 cells) for 30 min at 4 °C. The cells were
suspended in 4 ml of RPMI and placed in contact with iMagnet
for 8min. TheCD4Tcells obtained by negative selectionwere
of 92% purity, as confirmed by flow cytometry.
Real-time PCR—RNA from the cell pellet or tissue sample
was isolated using TRIzol reagent according to the instructions
of the manufacturer. Isolated RNA was reverse-transcribed to
cDNA with the help of a cDNA synthesis kit. cDNA was ana-
lyzed for the expression of Foxp3, Smad7, T-bet, SOCS1,
ISG15, IRF-1, IRF-7, TNF-, IFN-, and IL-6 by a Quantifast
SYBR Green PCR kit with the help of a Realplex master cycler
(Eppendorf, Hamburg, Germany). The following sequences
were used: T-bet, 5-CTAAGCAAGGACGGCGAAT-3 (for-
ward) and 5-TTCCACACTGCACCCACTT-3 (reverse);
TNF-, 5-GAACTGGCAGAAGAGGCACT-3 (forward) and
5-AGGGTCTGGGCCATAGAACT-3 (reverse); Foxp3, 5-
TTCATGCATCAGCTCTCCAC-3 (forward) and 5-CTGG-
ACACCCATTCCAGACT-3 (reverse); IFN-, 5-TGAACG-
CTACACACTGCATCTT-GG-3 (forward) and 5-CGACTC-
CTTTTCCGCTT-CCTGAG-3 (reverse); -actin, 5-AGAG-
GGAAATCGTGCGTGAC-3 (forward) and 5-CAATAGTG-
ATGACCTGGCCGT-3 (reverse); Smad7, 5-AAGTGTTCA-
GGTGGCCGGATC-TCAG-3 (forward) and 5-ACAGCAT-
CTGGACAGC-CTGCAGTTG-3 (reverse); SOCS1, 5-ACC-
TTCTTGGTGCGCGAC-3 (forward) and 5-AAGCCATCT-
TCACGCTGAGC-3 (reverse); IRF1, 5-CAGAGGAAAGAG-
AGAAAGTCC-3 (forward) and 5-CACACGGTGACAGTG-
CTGG-3 (reverse); IRF7, 5-CTGGAGCCATGGGTAT-
GCA-3 (forward) and 5-AAGCACAAGCCGAGACT-
GCT-3 (reverse); and ISG15, 5-GGAACGAAAGGGGCCA-
CAGCA-3 (forward) and 5-CCTCCATGGGCCTTCCCT-
CGA-3 (reverse). Ct values of experimental samples were nor-
malized against -actin, and analysis was done by comparative
Ct method. Results are represented in the form of relative
expression (fold).
ELISA—The cytokines IFN-, TNF-, and IL-17 secreted in
the culture supernatants were determined by sandwich ELISA.
Briefly, ELISA plates were coated with the appropriate concen-
tration of specific Ab in phosphate buffer (pH 9.2) for 12 h at
4 °C. Later, the plates were blocked with BSA (1%) to eliminate
nonspecific binding. ELISA plates were incubated with culture
supernatants and appropriate standards for 12 h at 4 °C. The
plates were treated with respective biotin-conjugated second-
ary Abs, followed by streptavidin-HRP. The plates were devel-
oped with the help of the substrate H2O2 and the chromogenic
agent O-phenylenediamine. The optical density of color devel-
opment was measured at 495 nm. Each step was followed by
washing five times with 1 PBS-Tween 20 (0.05%) and regular
incubation steps. The level of cytokines was estimated by plot-
ting a standard curve using recombinant cytokines and
expressed as picograms/milliliter.
EMSA—The IFN--mediated STAT1 response was mea-
sured by initially incubating CD4 T cells with CaeA (0–0.31
M) for 24 h, followed by IFN- (200 units/ml) stimulation for
30 min. To evaluate the TGF--mediated Smad3 response,
CD4T cells were incubated initially with CaeA (0–0.31M) for
24 h, followed by IFN- (200 units/ml) treatment for 48 h.
Later, cells were pulsed with TGF- (2 ng/ml) for 1 h. As a
positive control for STAT1 suppression, cells were also cul-
tured with the JAK inhibitor pyridone 6. Immediately thereaf-
ter, the nuclear extract was prepared, and EMSA was per-
formed, as described elsewhere (29). Briefly, the nuclei of cells
were isolated by suspending cells in hypotonic conditions in
buffer A (20 mM HEPES (pH 7.4), 0.42 M NaCl, 1.5 mM MgCl2,
0.2 mM EDTA, and 25% glycerol) containing the following pro-
teinase inhibitors: 0.5 mM dithiothreitol, 1 mM PMSF, 2 g/ml
leupeptin, and 10 g/ml aprotinin. Nuclear proteins were
extracted in buffer B (20 mM HEPES (pH 7.4), 50 mM KCl, 0.2
mM EDTA, 20% glycerol, and proteinase inhibitors) and used
for analysis of DNAbinding. The double-stranded oligonucleo-
tide of the consensus sequences 5-CATGTTATGCATATT-
CCTGTAAGTG-3 (STAT1) and 5-TCGAGAGCCAGA-
CAAAAAGCCAGACATTTAGCCAGACAC-3 (Smad3) was
used for EMSA. The double-stranded oligo was end-labeled
FIGURE 2. Tregs generated in the presence of CaeA suppress the activa-
tion and function of CD4 T cells. Tregs generated with the indicated con-
centrations of CaeA and in the absence (A) and presence (B) of TGF- were
culturedwith effector CD4 T cells (A and B) and alloreactive T cells (C).A and B,
the insets of the flow cytometry histograms depict the percentage of CD4/
CD69 T cells.C, bar diagram representingproliferation asmean S.D. of the
radioactivity incorporated (counts perminute,CPM) in alloreactive T cells. ***,
p 0.0001. The results are from two to three independent experiments.
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with [-32P]ATPwith the help of T4 polynucleotide kinase. The
binding reaction was carried out for 30 min at room tempera-
ture using nuclear extract (5g) along with a labeled probe in a
final volume of 20 l of buffer (10 mM Tris (pH 7.5), 0.1 mM
EDTA, 5 mM MgCl2, 80 mM KCl, 0.8 mM dithiothreitol, 2.5%
glycerol, and 1 g of poly(dI-dC)). The protein with the DNA
complex was separated in polyacrylamide gel (4%) using Tris
borate-EDTA buffer. After electrophoresis, the gel was dried
and exposed to the imager screen at room temperature for 12 h
and scanned using a PhosphorImager (Fujifilm, Tokyo, Japan).
Immunoprecipitation—CD4 T cells pulsed with IFN- for
15 min were lysed in radioimmune precipitation assay buffer.
The whole cell lysate was precleared using normal rabbit serum
and protein G-agarose beads for 1 h at 4 °C. Later, protein
G-agarose beads were separated from the lysate by centrifuga-
tion (5000 g, 5 min). The cell lysate was then incubated with
either anti-JAK1 or JAK2 Abs overnight at 4 °C. Protein G-aga-
rose beads were added and incubated for 1 h at 4 °C. The
immune complexeswere isolated by centrifugation (5000 g, 5
min). Purified complexes were boiled in SDS sample buffer and
FIGURE 3. CaeA-induced Treg expansion is not influenced by Th1 and Th17 polarizing conditions. Anti-CD3 and CD28 Ab-stimulated naïve CD4 T cells
were cultured under either Th1 (A) or Th17 (B) polarizing conditions with the indicated concentrations of CaeA. A, the data in the insets of the flow cytometry
contours depict an enhanced percentage of Foxp3 cells versus IFN- (A) and IL-17 (B) CD4 T cells. C and D, bar diagram representing mean  S.E. and
indicating an increase in the percentage of CD4/Foxp3 T cells under Th1 and Th17 polarizing conditions, respectively. E and F, a decrease in the percent
population of CD4 T cells expressing IFN- and IL-17 intracellularly. The results shown are from three independent experiments. *, p 0.05; **, p 0.005; ns,
not significant.
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used to analyze the phosphorylation of JAK1 and JAK2 proteins
by Western blotting.
Western Blotting—The expression of Smad7 and T-bet and
the phosphorylation of STAT1, STAT3, STAT4, Smad3, JAK1,
and JAK2were analyzed byWestern blotting. Briefly, the whole
cell lysate was prepared by suspending cells in radioimmune
precipitation assay buffer. The protein concentration was esti-
mated by Bradford assay. The equal concentration of protein
Caerulomycin A Enhances Treg Generation
17520 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 25•JUNE 20, 2014
 by guest on D
ecem
ber 12, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
lysate of all samples was separated on SDS-PAGE gels (12%)
followed by transfer to a nitrocellulose membrane at 4 °C for
12 h. Membrane transfer was followed by blocking with BSA
(5%) in PBS and then probing with their specific Abs, followed
by HRP-conjugated secondary Abs. The blots were visualized
by ECL Plus Western blotting substrate. The blots were devel-
oped onto x-ray film (Amersham Biosciences Hyperfilm ECL,
GE Healthcare). Internal loading was analyzed by stripping off
the primary Ab and reprobing with a suitable Ab.
Mitochondrial Membrane Potential Analysis—CD4 T cells
stimulatedwithanti-CD3 (2g/ml) andCD28 (1g/ml)Abswere
culturedwithCaeA(0–0.31M) for72h.Later, cellswerepelleted
and resuspended in JC-1 (5,5,6,6-tetrachloro-1,1,3,3-tetraeth-
ylbenzimidazolylcarbocyanine iodide) medium (2.5 g/ml). The
cultureswere incubatedat roomtemperature for15–20min in the
dark. Later, cells were washed with flow cytometry staining buffer
(2%FBS in PBS) and acquired immediately using a flow cytometer
(FACSCalibur), and then the analysis was done using FACSDiva
software. The increase in the mitochondrial membrane potential
was measured by the change in the fluorescence intensity of JC-1
from a green to a red wavelength.
Flow Cytometry—The cells were harvested from the cultures
and washed with flow cytometry buffer (PBS and 2% FBS). The
Fc receptor was blocked by using anti-CD16 Ab, followed by
staining with fluorochrome-conjugated anti-CD4 and CD69
Abs and their respective isotype-matched control Abs for 30
min at 4 °C. For staining with biotinylated Abs, cells were incu-
bated with biotin-conjugated Abs for 30 min at 4 °C, followed
by incubation with fluorochrome-conjugated streptavidin.
Finally, cells were washed and fixed in paraformaldehyde (1%).
Intracellular cytokine staining was performed by first staining
for surface markers followed by fixing with paraformaldehyde
(4%) for 20 min at 4 °C. Later, the cells were washed twice in
staining buffer and resuspended in permeabilizing buffer (1
PBS/0.1% saponin/1% FBS) at room temperature for 20 min.
This was followed by incubating with appropriate Abs or their
isotype-matched controls for 30 min. Cells were washed twice
with permeabilizing buffer and resuspended in staining buffer.
Nuclear protein Foxp3 staining was performed with a Foxp3
buffer staining kit according to the instructions of the manu-
facturer (eBioscience, San Diego, CA). Cells were acquired
using FACSCalibur or FACSAria II. Analysis was performed by
FACSDiva software.
Statistical Analysis—Statistical analysis was performed with
the help of GraphPad Prism software. The differences between
groups were compared by statistical analysis (two-tailed,
unpaired Student’s t test).
RESULTS
Induction of the Enhancement of Foxp3 CD4 T Cells by
CaeA—The expression of Foxp3 is crucial for the generation of
Tregs. Rapa is a known immunosuppressive drug that has been
reported to induce Treg formation (18). Hence, in the prelimi-
nary phase of the study, we tested whether CaeA can elicit the
generation of Tregs. Interestingly, we observed that anti-CD3
and CD28 Ab-stimulated naïve CD4 T cells cultured with
CaeA showed a significant (p 0.05) increase in Foxp3T cells
(cTregs) (Fig. 1A). Further, supplementing cultures with
TGF- significantly (p  0.005) promoted the pool of Foxp3
CD4Tcells (cTregs) (Fig. 1,A andB). The enhancement in the
frequency of Foxp3 CD4 T cells was observed in a dose-de-
pendent fashion. The data were reproduced by both flow
cytometry and RT-qPCR (Fig. 1 C). The results were compara-
ble with Rapa, which was used as a positive control (Fig. 1,
A–C). We also noticed an up-regulation of CD25 (IL-2 recep-
tor) expression on CD4 T cells on CaeA treatment, which was
augmented further on complementing the cultureswithTGF-
(data not shown). Intriguingly, naïve CD4 T cells cultured with
CaeA under Th1 and Th17 polarizing conditions exhibited a
significant decline in the expression (p  0.005) and secretion
(p  0.0001) of IFN- and IL-17 by CD4 T cells, respectively
(Fig. 1, D–F). Furthermore, down-regulation of CD44 and an
increased mitochondrial membrane potential was noticed in
CD4 T cells on treatment with CaeA (Fig. 1, G and H). T cell
activation (CD44hi) is inversely proportional to the mitochon-
drial membrane potential (30). We observed a similar effect
with CaeA.
Tregs Generated in the Presence of CaeA Significantly Sup-
pressed the Activity of Effector T Cells—We next checked
whether cTregs and cTregs were capable of inhibiting the
function of effector T cells. It is noteworthy that a diminished
expression ofCD69was observed on effectorCD4Tcells cocul-
tured with either cTregs or cTregs (Fig. 2, A and B). Further,
cTregs and cTregs substantially (p  0.0001) retarded the
alloresponse in a mixed lymphocyte reaction (Fig. 2 C). How-
ever, the extent of suppressionwas better in the case of cTregs
than cTregs. These data clearly signify that cTregs and cTregs
are functionally active andhave the potential to retard the activ-
ity of effector T cells.
CaeA Sufficiently Expands Foxp3 Tregs under Th1 and
Th17 Polarization Conditions—Loss of Tregs is one of themain
reasons for the breakdown of peripheral tolerance. The insta-
bility of Tregs under proinflammatory conditions is a major
hurdle for the restoration of tolerance by reprogrammed Tregs
FIGURE 4.CaeA ameliorated the symptoms of experimental arthritis by generating Tregs.Arthritis-inducedmicewere treatedwith CaeA. A, disease
progression/regression was monitored by clinical symptoms, as indicated under “Experimental Procedures.” Photos of the hind limbs only show
inflammation and swelling. B, line diagram representing the severity of disease on the basis of the clinical score (0, no symptoms; 1, mild erythema and
inflammation in the digits; 2, severity of inflammation up to the paw; and 3, severity of inflammation up to the ankle region). Error bars indicate the
mean  S.E. C, histopathology data representing H&E-stained sections of knee joints, showing decreased cell infiltration in the joint cavities of
CaeA-treated animals. D, bar diagram indicating a decrease in inflammation and synovitis by CaeA (nd, not detected). E, fluorescent tomographic
imaging of hind limbs probed with ProSense 680, signifying a decrease in disease severity by CaeA treatment. F, bar diagram representing the
quantification of inflammation in picomoles in the hind limbs using ProSense andOsteoSense.G, RT-qPCR data representing the fold change in the level
of cytokines in the knee joints of animals. H, data in the insets of the flow cytometry contour plots depict the increased percentage of CD4 T cells
expressing Foxp3 on CaeA treatment. I, ELISA data of cytokines are expressed as picograms/milliliter and depict the decreased yield of IFN- and TNF-
on treatment with CaeA. J, levels in picograms/milliliter of MMP-3 in serum as measured by ELISA. The results shown are from two to three independent
experiments with 5–6 mice/group. *, p  0.05; **, p  0.005; ***, p  0.0001.
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(31). Hence, proinflammatory conditions reciprocally regulate
Treg generation by favoring pathogenic Th17 cell development
(32). Hence it was crucial for us to monitor whether the pres-
ence of Th1 and Th17 polarizing cytokines can influence the
differentiation of CaeA-induced Tregs. It is of interest to note
that the proinflammatory milieu could not change the genera-
tion of Tregs (Fig. 3, A–D). In contrast, a significant reduction
was observed in the frequency of IFN-- and IL-17-producing
FIGURE 5. CaeA antagonized the IFN-- and IL-6-mediated STAT1 signaling pathway in CD4 T cells by enhancing SOCS1 expression. CD4 T cells
were treated with various concentrations of CaeA (0.04–0.31 M) for 24 h prior to the stimulation with IFN- (A and C) and IL-6 (B) for 15 min. A and B,
phosphorylation of STAT1 was analyzed by Western blotting. C, nuclear translocation by EMSA. The last lane indicating the inhibitor of JAK (iJAK)
represents pyridone 6, the positive control for STAT1 inhibition. D, Western blot images designating the phosphorylation of JAK1 and JAK2. The data in
the insets of the figures represent the fold change in phosphorylation (A, B, and D) and nuclear translocation (C). RT-qPCR data represented as bar
diagrams (mean  S.E.) illustrate the expression of SOCS1 (E), IRF1 (F), IRF7 (G), and ISG15 (H). The results shown are from three independent experi-
ments. *, p  0.05; p  0.005; ***, p  0.0001.
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T cells (Fig. 3, E and F). The response was observed to be in a
dose-dependentmanner (Fig. 3,A–F). The data denote that the
presence of the Th1 and Th17 differentiation cytokines IFN-
and IL-17, respectively, does not hinder the CaeA-induced for-
mation of Tregs.
CaeA Ameliorates Clinical Symptoms in an Experimental
Model of Arthritis—Th1 and Th17 cells play a potential role in
the progression of autoimmune diseases (33). In contrast, Tregs
are known to suppress autoimmunity (34). Because cTregs sup-
press both Th1 and Th17 cells, it was obvious to check whether
the administration of CaeA can restrain autoimmunity. In this
study, we used a collagen-induced animal model of arthritis.
Fascinatingly, therewas a regression in the clinical symptoms of
arthritis upon treatment with CaeA (Fig. 4A). The animals were
monitored for a clinical score over a period of 50 days (Fig. 4B).
Furthermore, this observation was supported by the histo-
pathological examination, which revealed decreased infiltra-
tion and less synovitis of the joint capsule of animals treated
with CaeA (Fig. 4,C andD). Furthermore, we substantiated our
finding by examining decreased inflammation by employing a
whole body fluorescence imager and probing with biomarkers
specific for cathepsins (ProSense) and bone remodelling (Oste-
oSense). The inflammatory response was decreased consider-
ably (p 0.005)with an increased dose of CaeA (Fig. 4,E and F).
Further, compared with control mice, the level of the proin-
flammatory cytokines IL-6, TNF-, and IFN-was lower in the
joint capsule of animals treated with CaeA (Fig. 4G).
During the early onset of disease (30 days), we also enumer-
ated the frequency of Tregs in the draining lymph nodes. The
results showed that animals treated with CaeA exhibited, in
vivo, an increased percentage of Tregs (Fig. 4H). In contrast, a
decline in the yield of IFN- and TNF- was noticed when
challenging cells with collagen in vitro (Fig. 4I). We also
observed a reduction in the serum levels of matrix metallopro-
teinase-3 in mice that received CaeA (Fig. 4J). Secretion of the
proinflammatory marker matrix metalloproteinase-3 has been
reported to be inhibited by Tregs (35). In essence, these results
(Fig. 4, A–J) indicate categorically that CaeA restrains arthritis
symptoms by inducing the generation of Tregs and suppressing
proinflammatory factors.
CaeA Specifically Interferes with STAT1 Signaling—The
cytokine milieu plays an important role in the lineage commit-
ment of CD4 T cells. Furthermore, cytokines exert signaling
through a group of conserved proteins known as STATs.
Hence, we next examined whether CaeA influences cytokine-
mediated signaling of STATs. Interestingly, CD4 T cells prein-
cubated with different concentrations of CaeA significantly
(p  0.005) inhibited the phosphorylation of STAT1 signaling
mediated by IFN- and IL-6 (Fig. 5, A and B). To further cor-
roborate the effect of CaeA on STAT1, we quantified the bind-
ing of STAT1 to its DNA with an enriched nuclear protein
lysate of IFN--treated CD4 T cells. We observed decreased
STAT1 binding to DNA, substantiating the observation (Fig.
5C) that CaeA specifically antagonizes STAT1 signaling. The
inhibitor of JAK pyradone 6, used as a positive control, also
showed inhibition of STAT1 binding to DNA. No change was
observed in the phosphorylation of JAK1/2 by CaeA (Fig. 5D).
The suppressor of cytokine signaling 1 (SOCS1) expression lev-
els were augmented with CaeA (Fig. 5E). SOCS1 has been
reported to antagonize interferon signaling by preventing the
phosphorylation of STAT1 by JAK1/2 (36, 37).We also studied
the expression of IFN-dependent genes like ISG15, IRF-1,
IRF-3, and IRF-7. It was observed that the levels of ISG15,
IRF-1, and IRF-7 were suppressed on CaeA treatment (Fig. 5,
F–H). No change was observed in the case of IRF-3 (data not
shown). Furthermore, CaeA treatment failed to alter IL-6- and
IL-12-mediated STAT3 and STAT4 signaling, respectively (Fig.
6, A and B), thus confirming the specificity of CaeA and its
interference in STAT1 signaling.
CaeA Interferes with IFN- Stimulation and Suppresses the
Expression of FasL, Smad7, and T-bet—STAT1 is an important
transcription factor for IFN--mediated signaling. Because
CaeA inhibits STAT1 phosphorylation, we next examined the
status of IFN--induced FasL, Smad7, and T-bet expression.
The expression of FasL is under the control of IFN--mediated
STAT1 signaling (38, 39). CaeA significantly (p  0.05) sup-
pressed FasL expression (Fig. 7,A and B). RT-qPCR data depict
a dose-dependent decrease in the levels of Smad7 and T-bet
with CaeA treatment (Fig. 7, C and D). We further supported
these results with Western blotting experiments (Fig. 7, E and
F). Overall, the results of these experiments indicate that CaeA
interferes with the IFN--mediated signaling pathway and
genes under the control of STAT1 (Fig. 7, A–F).
CaeA Enhances TGF--mediated Smad3 Signaling—TGF-
differentiates Tregs through Smad3 signaling (40). CaeA syner-
gizes with TGF- in the lineage commitment of Tregs (Fig. 1,
A–C). Therefore, we studied the role of CaeA in bolstering
TGF--mediated Smad3 signaling. CaeA significantly en-
hanced TGF- induced Smad3 phosphorylation of activated
CD4T cells (Fig. 8A). IFN- inhibits TGF--elicited phosphor-
ylation of Smad3 (41). However, increased TGF--induced
Smad3 phosphorylation was noticed with CaeA treatment (Fig.
FIGURE 6. CaeA does not operate through IL-6- and IL-12-mediated
STAT3 and STAT4 signaling pathways in CD4 T cells. CD4 T cells were
treated with various concentrations of CaeA (0.04–0.31 M) for 24 h prior to
IL-6 and IL-12 stimulation (15min). Phosphorylation of STAT3 (A, pSTAT3) and
STAT4 (B, pSTAT4) was performed by Western blotting. The data in the insets
of the images represent the fold change in phosphorylation. The results
shown are from three independent experiments.
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8B). This signifies categorically thatCaeAneutralizes the IFN-
effect. These results were authenticated further by nuclear
translocation of Smad3 (Fig. 8C). SIS3 is a Smad3 inhibitor,
therefore we used it as a positive control to prove the specificity
of Smad3 binding to DNA (42). IFN- also impedes the gener-
ation of Tregs (43). Consequently, the role of CaeA in rescuing
Tregs from IFN--influenced suppression was studied.
Remarkably, CaeA treatment significantly (p 0.005) rescued
the Tregs from the inhibitory effect of IFN-, as evidenced by
an increased percentage of Foxp3CD4Tcells (Fig. 8,D andE).
We also explicitly ascertained the authenticity of CaeA-in-
duced formation of Tregs by SIS3. The results establish cate-
gorically that the Tregs generated by CaeA are entirely depen-
dent on Smad3 activity, as verified by a noteworthy (p 0.005)
retardation of Foxp3 cells (Fig. 8, F and G). Consequently, it
may be concluded from the data that CaeA can neutralize the
suppressive action of IFN- in TGF--mediated Smad3 signal-
ing and, thus, helps in rescuing Tregs.
DISCUSSION
It has been reported recently that autoimmune diseases have
increased considerably in the developed world (44). Further-
more, women suffer three times more than men from autoim-
mune diseases. Autoimmune diseases can inflict debilitating
damage to body components. These diseases can influence vir-
tually any part of the body, including the brain/nervous system
(multiple sclerosis), heart (myocarditis), pancreas (type 1 dia-
betes), joints (rheumatoid arthritis), and multiple organs (sys-
temic lupus erythematosus) (45). Several therapies are available
for the treatment of autoimmune diseases. However, it is unfor-
tunate that existing therapies have severe side effects (6). For
example, more than 100,000 Americans are hospitalized annu-
ally because of the side effects of ulcers and gastrointestinal
bleeding. As a result, 7000–10,000 of them die because of drug-
inflicted injuries (46). With limited options for drug therapy, it
is an urgent need and a challenge for the scientific community
to identify alternative therapies that can effectively and safely
control and cure autoimmune diseases.
Recently, the role of Tregs has been linked successfully to
immune suppression (47–48). Further, Tregs can effectively
impede the function of Th1 and Th17 cells. Th1 and Th17 cells
play important role in provoking autoimmune diseases (49).
Furthermore, Tregs can be generated successfully in vitro.
Therefore, this strategy can be used as a possible remedial
measure to treat autoimmune diseases. Unfortunately, such
Tregs were unstable and lost their regulatory properties (32).
Class-specific depletion of gutmicrobiota and cytophage-flavo-
FIGURE 7. CaeA interferes with IFN- treatment and suppresses FasL, Smad7, and T-bet expression. CD4 T cells were treated with CaeA (0.04–0.31 M)
and examined for the expression of FasL, Smad7, and T-bet.A and B, flow cytometry histograms andbar graphdepicting the reducedpercentage of FasLCD4
T cells. C and D, bar diagrams indicating themean S.E. of the fold change expressionmonitored by RT-qPCR of Smad7 and T-bet, respectively. E and F, data
in the insets of the Western blot analyses depict the fold change in the expression of Smad7 and T-bet, respectively. The results presented are from three
independent experiments. *, p 0.05; **, 0.005; ***, 0.0001; ns, not significant.
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bacter-bacteroidetes by vancomycin treatment has also been
known to suppress Th17 differentiation and induction of Tregs
in vivo (50). The change in the gutmicrobiota also enhances the
susceptibility to allergic asthma (51). Hence, a regular search is
being undertaken to identify safer and better methods for gen-
erating stable Tregs (14). For this reason, we identified CaeA,
which can successfully generate stable and functional Tregs in
vitro and in vivo. Consequently, the following major observa-
tions were made during the study with CaeA: the induction of
the generation ofTregs individually and in concertwithTGF-,
the suppression of Th1 and Th17 cells, the amelioration of
experimental arthritis, the inhibition of the IL-6- and IFN--
mediated STAT1 phosphorylation, and the augmentation of
TGF--induced signaling of Smad3.
In this study, we demonstrated the vis-à-vis impact of
CaeA on the generation of Tregs. Interestingly, CaeA suc-
cessfully induced the formation of Tregs. Additionally, CaeA
exhibited a synergism with TGF- and further substantiated
the augmentation in the pool of Tregs. We further authenti-
cated the role of CaeA in generating Tregs by increased
mitochondrial membrane potential (lipid peroxidation). It
has been reported that Tregs rely on lipid peroxidation (30).
Further, the presence of CD44hi-expressing effector T cells
has a negative effect on Tregs (52). However, we noticed that
CaeA down-regulated CD44 on activated CD4 T cells, even-
tually favoring Treg generation. Furthermore, we demon-
strated that cTregs were functionally competent because
they inhibited the activation of effector T cells and sup-
pressed alloreactivity.
It has been reported that gene expression elicited by cyto-
kines can program T cell differentiation by their respective
transcription factors. The cytokines IL-12IFN-, TGF-,
and IL-6TGF- are known to favor the differentiation of
naïve CD4 T cells to Th1, Tregs, and Th17, respectively (16,
53, 54). IFN- induces the activation of the transcription
factor STAT1 through its receptor-associated protein tyro-
sine kinase JAK1 (55). The inhibitor for the JAK-STAT path-
way, tofacitinib, is used to treat rheumatoid arthritis patients
(56, 57). Suppressors of cytokine signaling (SOCS) are a spe-
cial class of proteins responsible for the inhibition of cyto-
kine signaling by preventing the phosphorylation of STATs
(36). SOCS1 specifically antagonizes interferon signaling by
inhibiting the phosphorylation of STAT1 (37). T-bet is a
transcription factor that is strongly induced by STAT1 and is
essential for the differentiation of Th1 and Th17 cells (58).
IL-6 transduces the signal through the transcription factor
STAT3 and also shares the STAT1 signaling pathway (59),
whereas TGF- signals through a cascade of the transcrip-
tion factors Smad2, Smad3, and Smad4 (40). Hence, on the
basis of these earlier findings, we next established the mech-
anism of action operating in the CaeA-mediated generation
of Tregs. Remarkably, our results demonstrate that CaeA
antagonizes the phosphorylation of the transcription factor
STAT1 induced by IFN- and IL-6. Our results showed the
enhanced expressionof SOCS1byCaeA. SOCS1 is responsible for
the stabilization of Foxp3 by controlling Th1 and Th17 differenti-
ation and suppressing STAT1 phosphorylation (60), therefore
indicating that CaeA inhibits the differentiation of both Th1 cells
and Th17 cells by increasing SOCS1. IFN--mediated phosphor-
ylation of STAT1 leads to the expression of T-bet, Smad7, and
FasL (61, 62). Intriguingly, CaeA treatment down-regulated the
exhibition of T-bet, Smad7, and FasL. It signifies that CaeA con-
trols the expression of T-bet, Smad7, and FasL by antagonizing
STAT1. It has been reported that Smad7 is responsible for the
inhibition of the regulatory function of Tregs (63). Interestingly, it
was noted that CaeA decreased the level of Smad7. This may be
correlated with the enhanced suppressive ability of cTregs.
The signaling events triggered by TGF- are regulated
negatively by IFN- (62). Phosphorylation of STAT1 induces
transcription of Smad7, which is a negative regulator for the
cascade of Smad3-mediated TGF- signaling (64). Interest-
ingly, CaeA suppressed IFN- induced Smad7 expression.
Further, CaeA rescued inhibition of the Smad3 cascade,
induced by IFN--mediated Smad7 signaling. This indicates
that CaeA inhibits the neutralizing effect of IFN- on TGF-
-mediated Smad3 signaling and, thereby, promotes the
generation of Tregs. It is also known that IFN- induces
reactive oxygen species generation, which interferes with the
formation of Tregs (43). Remarkably, it was noticed that
CaeA suppressed the release of reactive oxygen species and,
therefore, may be supporting the generation of Tregs, even
in the presence of IFN- (data not shown). SIS3 is an inhib-
itor of Smad3-mediated signaling of TGF-. Finally, we
established the specificity of CaeA-mediated Smad3 induc-
tion of the generation of Tregs by using SIS3. We noticed a
significant decline in the frequency of Foxp3 Tregs. These
data categorically authenticate the specificity of CaeA-in-
duced generation of Tregs. We report here, for the first
time, that suppression of IFN--mediated STAT1 leads to
enhanced Smad3 activity, thereby increasing the Foxp3
Treg population. In essence, our signaling data provide
insights into the mechanism of action of induction of Tregs
by CaeA by stimulating the Smad3 pathway.
Although Tregs are known to regulate the suppression of
the immune system, this property is not very well retained in
vivo (47, 48, 65). Furthermore, it is also known that the pres-
ence of the proinflammatory cytokines IL-6, IL-12, and
IFN- can influence the stability of Tregs. Therefore, this
may limit their application for treating autoimmunity (31–
32). Hence, it was very important for us to monitor the in
vivo stability of cTregs. Interestingly, our study revealed that
cTregs were not affected by the IL-6, IL-12, and IFN-
FIGURE 8. CaeA synergizes with TGF--mediated Smad3 signaling and rescues Tregs from IFN--mediated suppression.Naïve CD4 T cells cultured for
48 hwith different concentrations of CaeAwere stimulated either with anti-CD3 and CD28 Abs (A) or IFN- (B and C). A and B, cultures were pulsedwith TGF-
for an additional 60 min andWestern blotting was performed for Smad3 phosphorylation. C, nuclear translocation by EMSA. SIS3 was used as an inhibitor for
Smad3.D and E, Tregswere generated in thepresence of IFN-. The data of Foxp3 T cells represented as percent (E) in the insetsof the flow cytometry contour
plots andmean S.E. in the bar diagrams (E) indicate rescuing of Tregs by CaeA from IFN--induced suppression of the cells. Flow cytometry contour plots (F)
and data in the bar diagram (mean S.E.) (G) represent the decrease in the percentage of Foxp3 CD4 T cells in the presence of SIS3. *, p 0.05; p 0.005.
Results are representative of three independent experiments.
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milieu. These conditions favor the differentiation of Th17
and Th1 cells, respectively. We also demonstrated that CaeA
can directly suppress the generation of Th1 and Th17 cells.
We proved the functionality of cTregs in vivo in an experi-
mental model of arthritis. It is worth mentioning here that the
animals treated with CaeA exhibited a significant inhibition of
arthritis, as evidenced by decreased inflammation and clinical
symptoms. Interestingly, these animals also showed an en-
hanced population of Foxp3 Tregs. Overall, our study indi-
cates that CaeA may be a potent future immunotherapeutic
agent for treating arthritis by inducing the generation of Tregs.
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